ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL

Shuji Terai

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

An open-label study of five ulcerative colitis patients refractory to TNF antagonists found that add-on endoscopic submucosal injections of GUT-1, an RNA oligonucleotide inhibitor of CHST15, induced endoscopic improvement in 80% and clinical remission in 60% at week 6.

KEY POINTS

- GUT-1 at 250 nM was administered by endoscopic submucosal injection at weeks 0, 2, and 4 in five patients with moderate-to-severe UC who had lost response to ongoing TNF antagonist maintenance therapy (infliximab or adalimumab)
- At week 6, the endoscopic subscore decreased from 2.4 to 1.0 and the modified Mayo Score decreased from 7.8 to 1.3, with 80% achieving endoscopic improvement and 60% achieving clinical remission
- Three patients maintained clinical response for 48 weeks without recurrence, while two experienced recurrence at weeks 36 and 44
- All three corticosteroid-dependent patients remained off corticosteroids for at least 20 weeks after achieving clinical remission, and GUT-1 was well tolerated
- This small open-label study may interest clinicians managing TNF antagonist-refractory UC patients

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/d3ae858e-743c-11ee-ac8e-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.